The UCSF Alzheimer's Disease Research Center (ADRC) has made remarkable progress in our first 9 years, developing diagnostic approaches to dementia that are elucidating the phenotypic, genetic and molecular heterogeneity of Alzheimer's disease (AD), frontotemporal dementia (FTD), and Creutzfeldt-Jakob disease (CJD). The unique clinical cohorts, biospecimens, and images that we collect in the ADRC have facilitated these successes. Talented scientists mentored through our ADRC are making major contributions to the understanding of dementia. ADRC research has steadily increased. We are defining distinctive clinical subtypes of AD, FTD, and CJD that predict specific molecular and physiological mechanisms for dementia, while improving early recognition and tracking of transitions from normal aging to mild cognitive impairment (MCI) and dementia. These efforts will continue in parallel with drug development and pursuit of clinical trials with researchers who work with the ADRC. We will explore the heterogeneous features of AD, FTD-spectrum disorders, and CJD in the early stages with the goal of predicting their physiological, genetic, and molecular underpinnings. We will leverage cohorts in the ADRC and the powerful neuroscience community at UCSF and beyond to stimulate new diagnostic and treatment efforts for AD, FTD and CJD. We will increase understanding of the unique cultural and biological features of aging Chinese-Americans. We will develop innovative approaches to data management and biostatistics that we will share. The Education Core will be responsible for training new dementia leaders, while educating the medical and lay communities about non-AD dementias and non-amnestic subtypes of AD. We will perform three new projects: Project 1: Dr. Gil Rabinovici will compare and contrast early onset AD, late onset AD, and apoE4+ versus apoE4- patients to improve diagnostic accuracy in AD. Project 2: Dr. Marilu Gorno-Tempini will study developmental and immunological factors that influence the phenotype in PPA. Project 3: Dr. Yadong Huang will reprogram human skin fibroblasts into induced pluripotent stem cells and convert them into neurons from E4/E4 or E3/3 patients and healthy controls. Pathological substrates and gene expression will be compared.

Public Health Relevance

The UCSF ADRC will focus on Alzheimer's (AD) and related dementias. We bring unique skills to early diagnosis, improved clinical and imaging tests and new treatment approaches. We bring exceptional educational programs to professionals, patients and families.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG023501-13
Application #
9054044
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Silverberg, Nina B
Project Start
2004-04-01
Project End
2019-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
13
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Neurology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
McKeever, Paul M; Schneider, Raphael; Taghdiri, Foad et al. (2018) MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer's Disease. Mol Neurobiol 55:8826-8841
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Iaccarino, Leonardo; Tammewar, Gautam; Ayakta, Nagehan et al. (2018) Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. Neuroimage Clin 17:452-464
Wang, Chengzhong; Najm, Ramsey; Xu, Qin et al. (2018) Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med 24:647-657
Bettcher, Brianne M; Johnson, Sterling C; Fitch, Ryan et al. (2018) Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. J Alzheimers Dis 62:385-397
Kim, Eun-Joo; Brown, Jesse A; Deng, Jersey et al. (2018) Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series. J Neurol 265:2960-2971

Showing the most recent 10 out of 590 publications